Bristol-Myers Squibb Company Ce (CELG-RI) P/E Ratio
As of May 28, 2026
TL;DR — CELG-RI P/E ratio is 0.0x
Bristol-Myers Squibb Company Ce (CELG-RI) currently trades at a trailing P/E of 0.0x (cheap (deep value)). Forward P/E is estimated at 0.0x. The implied earnings yield is 3333.33%. Trading below 10x earnings is the historical deep-value zone. Often signals either a genuine bargain or that earnings are about to fall — verify with cash flow and the Quality Triple Check.
Trailing P/E vs Forward P/E
Trailing P/E (TTM)
0.0x
Based on last 12 months of reported EPS
Forward P/E (est)
0.0x
Estimated next 12 months
PEG
N/A
P/E divided by EPS growth — under 1 = cheap
Trailing P/E uses the last 12 months of actual reported earnings — it is the most reliable number because the inputs have already happened. Forward P/E uses consensus analyst estimates for the next 12 months — useful for fast-growing companies whose past earnings understate their future, but vulnerable to estimate revisions. The PEG ratio (P/E divided by earnings growth) is the bridge: a PEG below 1.0 traditionally signals you're paying less per share than the business is growing per share.
10-Year Historical P/E
Over the past decade, CELG-RI has traded at a median P/E of roughly 2.0x. Today's reading of 0.0x is 99% below its own historical median. This is a useful relative anchor: paying less than the long-run average implies either a buying opportunity or a structural worry that the market has correctly priced in.
Series illustrated from current P/E. Full 10-year monthly history ships in the upcoming valuation-data ingest.
Industry Comparison
The Healthcare sector median P/E is roughly 22x. CELG-RI at 0.0x is currently ~100% below the sector — either a value opportunity or a sign of structural concerns the market has priced in..
Compare CELG-RI against every other Healthcare stock in the full sector list.
Interpreting CELG-RI's P/E
What "Cheap (deep value)" means here: Trading below 10x earnings is the historical deep-value zone. Often signals either a genuine bargain or that earnings are about to fall — verify with cash flow and the Quality Triple Check.
Decision rule: a low P/E by itself is not a buy signal. Always check the cash flow statement, the Quality Triple Check (Piotroski / Beneish / Altman) from the fundamentals page, and the intrinsic value (DCF margin of safety) before acting on a multiple alone.
Common pitfalls: trailing P/E can be flattered by one-off tax benefits, share buybacks, or asset sales. Forward P/E can be overstated by overly optimistic analyst estimates. Read at least two of the most recent quarterly earnings calls before treating either as truth.
Related CELG-RI analyses
Frequently asked about CELG-RI P/E
What is CELG-RI's current P/E ratio?↓
CELG-RI's trailing P/E ratio is 0.0x as of May 28, 2026, which we classify as "Cheap (deep value)". Trading below 10x earnings is the historical deep-value zone. Often signals either a genuine bargain or that earnings are about to fall — verify with cash flow and the Quality Triple Check.
Is CELG-RI's P/E ratio cheap or expensive?↓
Against the Healthcare sector median of ~22x, CELG-RI's 0.0x is materially below the sector — a discount of about 100%, which is either a real bargain or signals an earnings risk worth investigating.
What is the difference between trailing and forward P/E?↓
Trailing P/E (TTM) uses the last 12 months of actual earnings — backward-looking but reliable. Forward P/E uses consensus analyst estimates for the next 12 months — more useful for growth stories but vulnerable to estimate revisions. Most value investors anchor on trailing P/E and use forward P/E as a sanity check.
How is P/E related to earnings yield?↓
Earnings yield = 1 / P/E. For CELG-RI at 0.0x P/E, earnings yield is roughly 3333.33%. This is comparable to a bond yield: it tells you the "earnings return" you'd get if you bought the whole company at this price.
When is P/E the wrong metric to use?↓
P/E breaks down for companies with negative earnings, heavy non-cash items, one-off events (restructuring, write-downs, tax benefits), banks (where book value and P/B are more appropriate), and high-CapEx commodity businesses (where EV/EBITDA is more comparable). Always cross-check P/E with at least one other valuation lens.